Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study

Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study

Background: There have been studies reporting the crucial roles of Dipeptidyl-peptidase 4 (DPP4) in colorectal cancer (CRC) initiation and progression, whereas DPP4-inhibitors are safe Food and Drug Association (FDA)-approved drugs for treating diabetes. This study aims to investigate the associatio...

Full description

Bibliographic Details
Main Authors:	Lui Ng, Dominic Chi-Chung Foo, Carlos King-Ho Wong, Abraham Tak-Ka Man, Oswens Siu-Hung Lo, Wai-Lun Law
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Cancers
Subjects:	colorectal cancer DPP4 CD26 DPP4-inhibitor gliptin immune cell
Online Access:	https://www.mdpi.com/2072-6694/13/14/3588

Similar Items

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
by: Fausto Chiazza, et al.
Published: (2018-05-01)

Heart failure hospitalization with DPP-4 inhibitors: A systematic review and meta-analysis of randomized controlled trials
by: Awadhesh Kumar Singh, et al.
Published: (2019-01-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Clinical Use of DPP-4 Inhibitors
by: Baptist Gallwitz
Published: (2019-06-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022-11-01)

Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26?
by: M. Maia Pinheiro, et al.
Published: (2020-04-01)

DPP4 Regulates the Th17/IL-17 Axis and Accelerates Epithelial Mesenchymal Transition to Promote Ovalbumin-Induced Asthma in Female C57BL/6J Mice
by: Linqiao Li, et al.
Published: (2023-12-01)

DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
by: Jianqiang Zhang, et al.
Published: (2019-05-01)

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
by: Sharma A, et al.
Published: (2022-06-01)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
by: Kunika Saini, et al.
Published: (2023-05-01)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021-12-01)

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients
by: Antti Nätynki, et al.
Published: (2022-07-01)

The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells
by: Guranda Chitadze, et al.
Published: (2021-11-01)

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study
by: Rohit Bishnoi, et al.
Published: (2019-07-01)

DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma
by: Jiali Carrie Huang, et al.
Published: (2021-04-01)

Integrated Analysis Identifies DPP7 as a Prognostic Biomarker in Colorectal Cancer
by: Wei Zhang, et al.
Published: (2023-08-01)

A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2
by: Cecy R Xi, et al.
Published: (2020-11-01)

Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review
by: Srinivasan Vedantham, et al.
Published: (2018-10-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring
by: Arumugam Kodimuthali, et al.
Published: (2010-07-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
by: Jonathan V. Mui, et al.
Published: (2021-10-01)

Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
by: Ayano Kubo, et al.
Published: (2020-09-01)

Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF‐PU.1‐DPP4 Axis
by: Lihua Wang, et al.
Published: (2021-10-01)

Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4
by: Zhaokai Wang, et al.
Published: (2017-05-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

The serum concentration and activity of DPP4 is positively related with the severity of hyperthyroidism in patients with Graves’ disease
by: Xiaona Chang, et al.
Published: (2023-12-01)

DPP4 as a Potential Candidate in Cardiovascular Disease
by: Chen SY, et al.
Published: (2022-09-01)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
by: Alba Sebastián-Martín, et al.
Published: (2022-08-01)

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
by: Mei-Tzu Wang, et al.
Published: (2017-07-01)

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
by: Vishal Mathur, et al.
Published: (2023-08-01)

Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26
by: Naveen Vankadari, et al.
Published: (2020-01-01)

Distinctive CD26 Expression on CD4 T-Cell Subsets
by: Oscar J. Cordero, et al.
Published: (2021-10-01)

Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas
by: Ivana Matrasova, et al.
Published: (2017-09-01)